secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001104659-22-045517
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA intends to rescind Breakthrough Therapy Designation for rusfertide; PN-943 Ph2 data due mid-May 2022
--------------------------------------------------------------------------------

- FDA notified Protagonist of intent to rescind Breakthrough Therapy Designation for rusfertide in polycythemia vera; company requesting meeting to appeal.
- PN-943 Phase 2 top-line data for ulcerative colitis expected in first half of Q2 2022 (by mid-May 2022).
- Rusfertide Phase 3 VERIFY study screening underway; no anticipated changes to development plan or timelines.
- Observed malignancies in rusfertide-treated patients explained; stopping rules align with background rates in PV population.
- Fast Track and Orphan Drug designations for rusfertide remain active.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922045517/0001104659-22-045517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922045517/tm2212619d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-045517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer